## GILD: Gilead Sciences, Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.22 indicates fundamental undervaluation. Quality metrics strong (ROE 41%, ROA 13%). Consistent execution (4/4 quarters beat estimates).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($118.11)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 6, Bearish: 0)

**1. GILEAD reaches three-year pricing agreement with US government**
- Source: StreetInsider | 20251219T200811 | Bullish | Relevance: 100%
- Gilead Sciences Inc. (NASDAQ: GILD) has secured a three-year agreement with the U.S. government to lower drug costs through discounted pricing on both existing and future medicines, particularly within the Medicaid program for treatments like HIV, Hepatitis C, Hepatitis B, and COVID-19. This deal also includes a launch of a Direct-to-Patient Program for Epclusa and an exemption from Section 232 pharmaceutical tariffs, contingent on further U.S. manufacturing investments. Gilead plans to invest $32 billion in U.S. manufacturing, R&D, and infrastructure, creating jobs and economic value, and will also provide HIV prevention medicine at no profit to individuals in affected countries through a partnership with the U.S. Department of State.

**2. Why Gilead Sciences (GILD) Stock Is Up Today**
- Source: FinancialContent | 20251219T200741 | Bullish | Relevance: 100%
- Shares of biopharmaceutical company Gilead Sciences (NASDAQ: GILD) surged 3.3% today following several positive developments. These include successful late-stage trial results for a new HIV treatment, regulatory approval for another HIV drug in the U.K., and a new pricing agreement with the U.S. government. The stock is currently trading near its 52-week high, up 35.5% since the beginning of the year.

**3. Gilead and U.S. Government Enter Agreement to Lower Costs of Medicines for Americans**
- Source: Business Wire | 20251219T192311 | Bullish | Relevance: 100%
- Gilead Sciences, Inc. announced an agreement with the U.S. government to reduce drug costs for Americans, aligning with President Trump's requests. The agreement includes discounts on existing medicines for U.S. Medicaid programs, pricing future medicines at parity with other developed nations, and a Direct-to-Patient Program for Epclusa®. Gilead also committed to further U.S. manufacturing investments in exchange for a three-year exemption from Section 232 pharmaceutical tariffs.

**4. Will GILD's Strong HIV Portfolio Reap Rewards in 2026?**
- Source: TradingView — Track All Markets | 20251219T130823 | Bullish | Relevance: 100%
- Gilead Sciences, Inc. (GILD) is poised for potential growth in 2026 due to its dominant HIV portfolio, spearheaded by therapies like Biktarvy, Descovy, and the newly approved injectable Yeztugo (lenacapavir). The company is also advancing a single-tablet regimen combining bictegravir and lenacapavir, which has shown promising results in late-stage trials. Despite strong competition from GSK and Merck in the HIV treatment landscape, Gilead's innovative approaches and valuation metrics suggest a potentially rewarding future.

**5. Czech National Bank Acquires 11,080 Shares of Gilead Sciences, Inc. $GILD**
- Source: MarketBeat | 20251218T100014 | Bullish | Relevance: 100%
- The Czech National Bank increased its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 3.6% in the third quarter, acquiring an additional 11,080 shares, bringing its total holdings to 315,140 shares valued at $34,981,000. Several other hedge funds also adjusted their positions in GILD. The article also provides a performance overview of Gilead Sciences, including its recent earnings, dividend announcement, insider transactions, and analyst ratings, which currently average a "Moderate Buy" with a consensus target price of $131.54.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-12 | Morgan Stanley | $151 | $147 | +3% |
| 2025-12-10 | Wells Fargo | $150 | $145 | +3% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-12 | Morgan Stanley | main | Overweight |
| 2025-12-10 | Wells Fargo | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 5 ($10.00M) |
| Sells | 14 ($6.13M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 45.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Vanguard Group Inc: 9.6% (-0.3%)
- Blackrock Inc.: 9.4% (+1.2%)
- FMR, LLC: 4.9% (+0.6%)
- State Street Corpora: 4.8% (-0.2%)
- Capital World Invest: 3.6% (-2.4%)

### Key Risks

1. Insider selling cluster: $6.1M in recent transactions.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Momentum building: MRS_20 improving +3.7% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.22 indicates undervaluation relative to growth. Quality metrics strong (ROE 41%, ROA 13%, margin 28%). Balance sheet: $4.0B free cash flow. Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $154.2B |
| Beta | 0.33 |
| 52W Range | $88.57 - $128.70 |
| Short Interest | 1.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.22 |
| Forward P/E | 14.2 |
| Current P/E | 15.2 |
| YoY Growth | 7.2% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from -2.6% to 1.2% (+3.7% in 5 days), confirming momentum buildup. Below STRENGTH zone by 2.8pp (needs >4.0% for momentum thesis). MRS_5 at 1.4% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 55. Elevated volume (1.8x 20MA), institutional activity likely. OFD pattern: +MUH (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 1.18% (CS: 63) | Neutral |
| RSI_14 | 55.1 | Neutral |
| MACD Histogram | -0.13 | Bearish |
| vs SMA20 | 1.010x | Above |
| vs SMA50 | 1.018x | Above |
| vs SMA200 | 1.097x | Above |

### Decision

- **Verdict:** HOLD
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $124.29
- **Stop Loss:** $118.11 (5.0% risk)
- **Target:** $136.65 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 194
- **Position Value:** $24,112.26
- **Portfolio %:** 24.11%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with improving risk appetite as VIX falls to 6th percentile and tech rally resumes on AI infrastructure demand. Fed pause expectations from cooling CPI data support equities, though elevated put/call ratio suggests cautious positioning. Focus on quality names in AI-exposed sectors.*

### Earnings

**Next:** 2026-02-10 (Est: $1.88)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.14 | $2.47 | +15.7% |
| 2025Q2 | $1.96 | $2.01 | +2.7% |
| 2025Q1 | $1.78 | $1.81 | +1.9% |
| 2024Q4 | $1.70 | $1.90 | +11.7% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*